Insider · CIK 0001903704
Mary Kuropatkin
Files at CFSB (CFSB Bancorp, Inc. /MA/). First filing -, latest -.
In brief
Mary Kuropatkin files SEC Form 4 as officer at CFSB (CFSB Bancorp, Inc. /MA/). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Mary Kuropatkin has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 31, 2025 | CFSB CFSB Bancorp, Inc. /MA/ | DDisposition to issuer Common Stock | -6,000 | - | - | 0 | Oct 31, 2025 |
| Oct 31, 2025 | CFSB CFSB Bancorp, Inc. /MA/ | DDisposition to issuer Common Stockindirect: By ESOP | -2,381 | - | - | 0 | Oct 31, 2025 |
| Oct 31, 2025 | CFSB CFSB Bancorp, Inc. /MA/ | DDisposition to issuer Common Stockindirect: By 401(k) | -9,940 | - | - | 0 | Oct 31, 2025 |
| Oct 31, 2025 | CFSB CFSB Bancorp, Inc. /MA/ | DDisposition to issuer Stock Optionsderivative | -14,000 | - | - | 0 | Oct 31, 2025 |
Questions about Mary Kuropatkin
Answered from the filings on this page, as of the latest one.
Is Mary Kuropatkin buying or selling?
Mary Kuropatkin has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Mary Kuropatkin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mary Kuropatkin has 0.
Where does Mary Kuropatkin file Form 4?
Mary Kuropatkin has filed Form 4 at CFSB (CFSB Bancorp, Inc. /MA/) as VP-Retail Banking. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.